SAREPTA THERAPEUTICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
SAREPTA THERAPEUTICS, INC. (SRPT) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2026-03-31 was 16.01M shares.
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-06-30 was 8.10M shares, a 466.04% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2024 was 9.29M shares.
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2023 was 0.00 shares.
- SAREPTA THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2022 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-08-05 | 16.01M shares 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | 16.01M shares 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 0.00 shares 10-K · filed 2026-03-02 | |||
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-06 | 0.00 shares 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | 8.10M shares 10-Q · filed 2026-08-05 | 0.00 shares 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 9.29M shares 10-K · filed 2026-03-02 | |||
| 2024-09-30 | 1.25M shares 10-Q · filed 2025-11-06 | 1.37M shares 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | 1.43M shares 10-Q · filed 2025-08-06 | 1.44M shares 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | 1.44M shares 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | 0.00 shares 10-K · filed 2026-03-02 | |||
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-11-06 | 0.00 shares 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | 0.00 shares 10-Q · filed 2024-08-07 | 0.00 shares 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-01 | |||
| 2022-12-31 | 0.00 shares 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |